baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ING Knock-Out Genmab AS/ DE000NG8L016 /

2024-08-02 4:44:15 PM	Chg.+0.520	Bid4:54:48 PM	Ask4:54:48 PM	Underlying	Strike price	Expiration date	Option type
13.720EUR	+3.94%	- Bid Size: -	- Ask Size: -	-	2,943.7825 DKK	2078-12-31	Put

GlobeNewswire 06-28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...

GlobeNewswire 06-27 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...

GlobeNewswire 06-24 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...

GlobeNewswire 06-01 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...

GlobeNewswire 05-29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 05-21 Genmab Completes Acquisition of ProfoundBio

GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

GlobeNewswire 05-14 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...

GlobeNewswire 05-14 Immatics Announces First Quarter 2024 Financial Results and Business Update

GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 05-02 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...

GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

GlobeNewswire 04-03 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire 03-11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...

GlobeNewswire 03-07 BioNTech Announces Planned Retirement of Sean Marett

GlobeNewswire 03-06 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...

GlobeNewswire 03-04 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...

GlobeNewswire 02-14 Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire 02-14 Genmab Publishes 2023 Annual Report

GlobeNewswire 02-08 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...

ING Knock-Out Genmab AS/ DE000NG8L016 /

If you wish to receive reply to your feedback, please provide your email address.